July 24, 2025 a 05:00 pm
SYK: Analysts Ratings - Stryker Corporation
Stryker Corporation, a leading player in the medical technology sector, operates across MedSurg, Neurotechnology, Orthopaedics, and Spine segments. With a global footprint spanning approximately 75 countries, the company’s robust portfolio positions it well for continued growth. The current sentiment among analysts reflects a strong confidence in Stryker's ability to navigate market challenges.
Historical Stock Grades
The current month's data reflects a generally positive outlook for Stryker Corporation. The predominant sentiment leans towards bullish, with a substantial number of 'Buy' and 'Strong Buy' recommendations.
| Recommendation | Number of Ratings | Score |
|---|---|---|
| Strong Buy | 9 | |
| Buy | 13 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, sentiment towards Stryker Corporation has remained stable, with a consistent number of strong buy and buy ratings. - June and July 2025 maintained strong buy and buy ratings suggesting confidence in the company’s market position. - Ratings indicating hesitation, such as 'Hold,' have not shown a substantial rise, pointing towards a sustained belief in Stryker's strategic direction.
Percentage Trends
The distribution of ratings has been relatively stable over the past months, with a marked preference for 'Buy' and 'Strong Buy.' - Percentage of 'Buy' ratings has remained at approximately 41% each month from May to July 2025, indicating a consistent market sentiment. - Analysts' preference for 'Strong Buy' or 'Buy' shows continued confidence in the company, with negligible inclination towards 'Sell.'
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-08 | Outperform | Outperform | Evercore ISI Group |
| 2025-05-22 | Buy | Buy | Citigroup |
| 2025-05-05 | Market Perform | Market Perform | JMP Securities |
| 2025-05-05 | Hold | Hold | Truist Securities |
| 2025-05-02 | Buy | Buy | Roth MKM |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-12-02 | Overweight | Equal Weight | Morgan Stanley |
| 2024-05-22 | Buy | Hold | Needham |
| 2024-01-31 | Buy | Hold | Canaccord Genuity |
| 2023-09-05 | Buy | Neutral | B of A Securities |
| 2023-09-04 | Buy | Neutral | B of A Securities |
Interpretation
The overall analyst sentiment towards Stryker Corporation suggests a strong market confidence and a continued strategic growth trajectory. Positive recommendations, despite stable scores and minor fluctuations, point towards consistent trust in the company's operational effectiveness and innovative potential. The stability in ratings indicates minimal market uncertainty, with many analysts predicting a positive outlook.
Conclusion
In summary, Stryker Corporation continues to enjoy strong support from analysts, underscored by a consistent number of Buy and Strong Buy ratings. The market confidently backs Stryker's ongoing operational excellence and strategic vision. While recommendations have stabilized in recent months, the consistent bullish sentiment reflects the company's resilience and potential for sustained growth in the competitive medical technology sector.